ESMO Advanced Course on Cholangiocarcinoma: Where are we going? 

PROGRAMME
ESMO ADVANCED COURSE PROGRAMME

CHOLANGIOCARCINOMA: WHERE ARE WE GOING?

Barcelona, Spain
15-16 September 2023

CO-CHAIRS
Julien Edeline, France
Angela Lamarca, Spain

SPEAKERS
Chiara Braconi, United Kingdom
John Bridgewater, United Kingdom
Maeve Lowery, Ireland
Teresa Macarulla, Spain
Helen Morement, United Kingdom
Victor Moreno, Spain
Lorenza Rimassa, Italy
Arndt Vogel, Germany

LEARNING OBJECTIVES

• To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
• To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
• To discuss the role of locoregional therapy for cholangiocarcinoma
• To investigate the role of immunotherapy for the management of cholangiocarcinoma
• To explore currently available and novel targeted therapies and treatment options for advanced disease

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

SERVIER

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
09:00-09:10 Welcome and introduction
10’ Welcome and learning objectives
Julien Edeline, FR and Angela Lamarca, ES

09:10-10:30 Session 1 – Knowing cholangiocarcinoma and the patients
20’ What is cholangiocarcinoma (primary site, molecular biology, epidemiology)?
Teresa Macarulla, ES
20’ Symptom management when treating patients with cholangiocarcinoma
Julien Edeline, FR
20’ Patient perspective: What should the oncologist treating cholangiocarcinoma take into account?
Helen Morement, UK
20’ Discussion

10:30-11:00 Coffee break

11:00-12:00 Session 2 – Adjuvant and neoadjuvant treatment for cholangiocarcinoma
20’ Adjuvant treatment: Is capecitabine the standard of care?
John Bridgewater, UK
20’ Neoadjuvant treatment: Is perioperative treatment coming or could it have a role?
Lorenza Rimassa, IT
20’ Discussion

12:00-12:40 Session 3 – Locoregional therapies for cholangiocarcinoma
20’ Locoregional therapies: How can we improve the study design?
Julien Edeline, FR
20’ Discussion

12:40-13:40 Lunch

13:40-14:40 Session 4 – The management of advanced disease: Chemotherapy and immunotherapy
20’ Chemotherapy: First line and second line. How is the field moving forward?
Angela Lamarca, ES
20’ Immunotherapy: Rationale, current data, and upcoming studies
Arndt Vogel, DE
20’ Discussion

14:40-17:10 Session 5 – The management of advanced disease: Targeted therapies and new treatment options
20’ Targeted therapies FGFR and IDH: Current data and compounds in advanced (phase II and beyond) stage of development
Maeve Lowery, IE
20’ Targeted therapies beyond FGFR and IDH: Current data and compounds in advanced (phase II and beyond) stage of development
Chiara Braconi, UK

20’ Discussion

15:40-16:10 Coffee break

20’ What is coming – Phase I input – Novel IO strategies, cell therapy new compounds in phase I with potential activity
Victor Moreno, ES

20’ Ongoing clinical trials – Ongoing and soon-to-come phase II and phase III: To which trials shall I recruit my patients?
Teresa Macarulla, ES

20’ Discussion

17:10-18:10 Workshop session
Workshop session where clinical cases are presented by speakers with interactive questions and discussion with the audience

Workshop 1 Adjuvant therapy
Angela Lamarca, ES

20:00 Networking dinner

Saturday, 16 September 2023

09:00-11:30 Workshop session
Two parallel workshop sessions with 30 delegates in each group (delegates will attend the two sessions on a rotational basis)
60’ Workshop time

Workshop 2 Palliative chemotherapy (+/- immunotherapy)
Julien Edeline, FR and Lorenza Rimassa, IT

10:00-10:30 Coffee break

Workshop 3 Targeted therapy
Chiara Braconi, UK and Maeve Lowery, IE

11:30-12:00 Feedback on the workshops from each group

12:00-12:15 Synthesis and wrap-up
Julien Edeline, FR

12:15-13:15 Lunch